{"nctId":"NCT00500318","briefTitle":"A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2007-07"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"count":181,"armGroups":[{"label":"Aclidinium","type":"EXPERIMENTAL","interventionNames":["Drug: Aclidinium Bromide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Aclidinium Bromide","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A diagnosis of stable moderate to severe COPD (GOLD 2006); post-levalbuterol FEV1 \\>=30% and \\< 80% predicted and FEV1/FVC\\<70% predicted\n* Current or former cigarette smoker\n* Functional Residual Capacity (FRC) measured by body plethysmography \\>= 120% of predicted value\n* Baseline Dyspnea Index (BDI) focal score â‰¤ 7 at Visit 4\n\nExclusion Criteria:\n\n* History of presence of asthma, allergic rhinitis, or atopy\n* Hospitalization for acute COPD exacerbation in the 3 months prior to study entry\n* Respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks prior to study entry\n* Clinically significant respiratory conditions other than COPD\n* Chronic use of oxygen therapy \\>= 15 hours a day","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Exercise Endurance Time (ET)","description":"Exercise endurance time is defined as the time from the increase in work rate at 75% Wmax (watts) to the point of symptom limitation. The Wmax is defined as the highest work rate the patients were able to maintain for at least 30 seconds.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129.45","spread":"31.19"},{"groupId":"OG001","value":"13.01","spread":"30.97"}]}]}]},{"type":"SECONDARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1)","description":"Change in trough Forced Expiratory Volume in 1 second. FEV1 was assessed at the end of the daily dosing interval (Trough).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.090","spread":"0.018"},{"groupId":"OG001","value":"-0.010","spread":"0.018"}]}]}]},{"type":"SECONDARY","title":"Trough Inspiratory Capacity (IC)","description":"Change in trough Inspiratory Capacity. Inspiratory Capacity was measured as part of the spirometry procedures performed at each visit. IC was assessed at the end of the daily dosing interval (Trough).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.083","spread":"0.032"},{"groupId":"OG001","value":"-0.019","spread":"0.032"}]}]}]},{"type":"SECONDARY","title":"Functional Residual Capacity (FRC)","description":"Change in trough Functional Residual Capacity. FRC was assessed at the end of the daily dosing interval (Trough).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.138","spread":"0.061"},{"groupId":"OG001","value":"-0.076","spread":"0.064"}]}]}]},{"type":"SECONDARY","title":"Inspiratory Capacity (IC)/Total Lung Capacity (TLC) Ratio","description":"Ratio of trough Inspiratory Capacity verses Total Lung Capacity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.014","spread":"0.006"},{"groupId":"OG001","value":"-0.003","spread":"0.006"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":86},"commonTop":["Headache","Chronic Obstructive Pulmonary Disorder","Cough","Upper Respiratory Tract Infection"]}}}